Trial Profile
Bevacizumab Against Recurrent Retinal Detachment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Perflutren; Sulfur hexafluoride
- Indications Proliferative vitreoretinopathy; Retinal detachment
- Focus Therapeutic Use
- Acronyms BEARRD
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Planned End Date changed from 1 Apr 2020 to 15 Nov 2020.
- 15 Oct 2019 Planned primary completion date changed from 1 Oct 2019 to 15 Nov 2019.